key: cord-0958988-9ok153yl
authors: Tenforde, Mark W.; Self, Wesley H.; Naioti, Eric A.; Ginde, Adit A.; Douin, David J.; Olson, Samantha M.; Talbot, H. Keipp; Casey, Jonathan D.; Mohr, Nicholas M.; Zepeski, Anne; Gaglani, Manjusha; McNeal, Tresa; Ghamande, Shekhar; Shapiro, Nathan I.; Gibbs, Kevin W.; Files, D. Clark; Hager, David N.; Shehu, Arber; Prekker, Matthew E.; Erickson, Heidi L.; Gong, Michelle N.; Mohamed, Amira; Henning, Daniel J.; Steingrub, Jay S.; Peltan, Ithan D.; Brown, Samuel M.; Martin, Emily T.; Monto, Arnold S.; Khan, Akram; Hough, Catherine L.; Busse, Laurence W.; ten Lohuis, Caitlin C.; Duggal, Abhijit; Wilson, Jennifer G.; Gordon, Alexandra June; Qadir, Nida; Chang, Steven Y.; Mallow, Christopher; Rivas, Carolina; Babcock, Hilary M.; Kwon, Jennie H.; Exline, Matthew C.; Halasa, Natasha; Chappell, James D.; Lauring, Adam S.; Grijalva, Carlos G.; Rice, Todd W.; Jones, Ian D.; Stubblefield, William B.; Baughman, Adrienne; Womack, Kelsey N.; Lindsell, Christopher J.; Hart, Kimberly W.; Zhu, Yuwei; Stephenson, Meagan; Schrag, Stephanie J.; Kobayashi, Miwako; Verani, Jennifer R.; Patel, Manish M.; Calhoun, Nicole; Murthy, Kempapura; Herrick, Judy; McKillop, Amanda; Hoffman, Eric; Zayed, Martha; Smith, Michael; Settele, Natalie; Ettlinger, Jason; Priest, Elisa; Thomas, Jennifer; Arroliga, Alejandro; Beeram, Madhava; Kindle, Ryan; Kozikowski, Lori-Ann; De Souza, Lesley; Ouellette, Scott; Thornton-Thompson, Sherell; Tyler, Patrick; Mehkri, Omar; Ashok, Kiran; Gole, Susan; King, Alexander; Poynter, Bryan; Stanley, Nicholas; Hendrickson, Audrey; Maruggi, Ellen; Scharber, Tyler; Jorgensen, Jeffrey; Bowers, Robert; King, Jennifer; Aston, Valerie; Armbruster, Brent; Rothman, Richard E.; Nair, Rahul; Chen, Jen-Ting (Tina); Karow, Sarah; Robart, Emily; Maldonado, Paulo Nunes; Khan, Maryiam; So, Preston; Levitt, Joe; Perez, Cynthia; Visweswaran, Anita; Roque, Jonasel; Rivera, Adreanne; Frankel, Trevor; Howell, Michelle; Friedel, Jennifer; Goff, Jennifer; Huynh, David; Tozier, Michael; Driver, Conner; Carricato, Michael; Foster, Alexandra; Nassar, Paul; Stout, Lori; Sibenaller, Zita; Walter, Alicia; Mares, Jasmine; Olson, Logan; Clinansmith, Bradley; Rivas, Carolina; Gershengorn, Hayley; McSpadden, EJ; Truscon, Rachel; Kaniclides, Anne; Thomas, Lara; Bielak, Ramsay; Valvano, Weronika Damek; Fong, Rebecca; Fitzsimmons, William J.; Blair, Christopher; Valesano, Andrew L.; Gilbert, Julie; Crider, Christine D.; Steinbock, Kyle A.; Paulson, Thomas C.; Anderson, Layla A.; Kampe, Christy; Johnson, Jakea; McHenry, Rendie; Blair, Marcia; Conway, Douglas; LaRose, Mary; Landreth, Leigha; Hicks, Madeline; Parks, Lisa; Bongu, Jahnavi; McDonald, David; Cass, Candice; Seiler, Sondra; Park, David; Hink, Tiffany; Wallace, Meghan; Burnham, Carey-Ann; Arter, Olivia G.
title: Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021
date: 2021-08-27
journal: MMWR Morb Mortal Wkly Rep
DOI: 10.15585/mmwr.mm7034e2
sha: bc6495bace8c3add4b017e76f449e67ec2ae2b8e
doc_id: 958988
cord_uid: 9ok153yl

Real-world evaluations have demonstrated high effectiveness of vaccines against COVID-19-associated hospitalizations (1-4) measured shortly after vaccination; longer follow-up is needed to assess durability of protection. In an evaluation at 21 hospitals in 18 states, the duration of mRNA vaccine (Pfizer-BioNTech or Moderna) effectiveness (VE) against COVID-19-associated hospitalizations was assessed among adults aged ≥18 years. Among 3,089 hospitalized adults (including 1,194 COVID-19 case-patients and 1,895 non-COVID-19 control-patients), the median age was 59 years, 48.7% were female, and 21.1% had an immunocompromising condition. Overall, 141 (11.8%) case-patients and 988 (52.1%) controls were fully vaccinated (defined as receipt of the second dose of Pfizer-BioNTech or Moderna mRNA COVID-19 vaccines ≥14 days before illness onset), with a median interval of 65 days (range = 14-166 days) after receipt of second dose. VE against COVID-19-associated hospitalization during the full surveillance period was 86% (95% confidence interval [CI] = 82%-88%) overall and 90% (95% CI = 87%-92%) among adults without immunocompromising conditions. VE against COVID-19- associated hospitalization was 86% (95% CI = 82%-90%) 2-12 weeks and 84% (95% CI = 77%-90%) 13-24 weeks from receipt of the second vaccine dose, with no significant change between these periods (p = 0.854). Whole genome sequencing of 454 case-patient specimens found that 242 (53.3%) belonged to the B.1.1.7 (Alpha) lineage and 74 (16.3%) to the B.1.617.2 (Delta) lineage. Effectiveness of mRNA vaccines against COVID-19-associated hospitalization was sustained over a 24-week period, including among groups at higher risk for severe COVID-19; ongoing monitoring is needed as new SARS-CoV-2 variants emerge. To reduce their risk for hospitalization, all eligible persons should be offered COVID-19 vaccination.

On August 18, 2021, this report was posted as an MMWR Early Release on the MMWR website (https://www.cdc.gov/mmwr).

Real-world evaluations have demonstrated high effectiveness of vaccines against COVID-19-associated hospitalizations (1) (2) (3) (4) measured shortly after vaccination; longer follow-up is needed to assess durability of protection. In an evaluation at 21 hospitals in 18 states, the duration of mRNA vaccine (Pfizer-BioNTech or Moderna) effectiveness (VE) against COVID-19-associated hospitalizations was assessed among adults aged ≥18 years. Among 3,089 hospitalized adults (including 1,194 COVID-19 case-patients and 1,895 non-COVID-19 control-patients), the median age was 59 years, 48.7% were female, and 21.1% had an immunocompromising condition. Overall, 141 (11.8%) case-patients and 988 (52.1%) controls were fully vaccinated (defined as receipt of the second dose of Pfizer-BioNTech or Moderna mRNA COVID-19 vaccines ≥14 days before illness onset), with a median interval of 65 days (range = 14-166 days) after receipt of second dose. VE against COVID-19-associated hospitalization during the full surveillance period was 86% (95% confidence interval [CI] = 82%-88%) overall and 90% (95% CI = 87%-92%) among adults without immunocompromising conditions. VE against COVID-19-associated hospitalization was 86% (95% CI = 82%-90%) 2-12 weeks and 84% (95% CI = 77%-90%) 13-24 weeks from receipt of the second vaccine dose, with no significant change between these periods (p = 0.854). Whole genome sequencing of 454 case-patient specimens found that 242 (53.3%) belonged to the B.1.1.7 (Alpha) lineage and 74 (16.3%) to the B.1.617.2 (Delta) lineage. Effectiveness of mRNA vaccines against COVID-19-associated hospitalization was * These authors contributed equally to this report. sustained over a 24-week period, including among groups at higher risk for severe COVID-19; ongoing monitoring is needed as new SARS-CoV-2 variants emerge. To reduce their risk for hospitalization, all eligible persons should be offered COVID-19 vaccination.

Evaluations of authorized mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna) have consistently demonstrated high VE across diverse populations (1, 5) . Because COVID-19 vaccines were initially authorized in the United States in December 2020, evaluations of real-world effectiveness have been subject to a short period of postvaccination follow-up. Monitoring durability of protection after COVID-19 vaccination can help determine whether booster vaccines might be indicated, particularly with continued emergence of new variants that might overcome vaccine-induced immunity. In real-world settings, durability of protection has commonly been measured by comparing the odds of vaccination in laboratory-confirmed case-patients and control-patients who tested negative for infection, by time since vaccination (6, 7) .

During March 11-July 14, 2021, adults aged ≥18 years admitted to 21 hospitals in 18 states were included in an analysis of durability of vaccine-induced protection. Casepatients had COVID-19-like illness † and had received a positive SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) or antigen test result. A first group of hospital-based control-patients had COVID-19-like illness and had negative SARS-COV-2 results by all tests, including at least one RT-PCR test. A second hospital-based control group of patients without COVID-19-like illness (and therefore unlikely to be hospitalized for COVID-19-like illness) † COVID-19-like illness was defined as having one or more of the following: fever, cough, shortness of breath, loss of taste, loss of smell, use of respiratory support for the acute illness, or new pulmonary findings on chest imaging consistent with pneumonia.

was also enrolled (4). This second control group also received negative SARS-CoV-2 results by all tests, including at least one RT-PCR test. Eligibility for enrollment as a case-patient or one of these controls required SARS-CoV-2 testing within 10 days of symptom onset and hospital admission within 14 days of symptom onset. Final case/control status was determined using clinical testing results and central laboratory RT-PCR testing of upper respiratory specimens (nasal swabs or saliva) performed at a central laboratory (Vanderbilt University Medical Center, Nashville, Tennessee) (4). Specimens positive for SARS-CoV-2 with cycle threshold values <32 were sent to University of Michigan (Ann Arbor, Michigan) for whole genome sequencing and SARS-CoV-2 lineage determination (4). Patients or their proxies were interviewed about baseline demographic characteristics, clinical history (including COVID-19-like signs or symptoms experienced and date of illness onset), and history of COVID-19 vaccination. Vaccine was considered to have been administered if vaccination dates and product names were verified through medical records, state immunization registries, vaccination record cards, or provider or pharmacy records, or if plausibly reported by patient or proxy with date and location of vaccination. A patient was considered to be fully vaccinated if both doses of an authorized mRNA COVID-19 vaccine were administered, with the second dose received ≥14 days before illness onset. § Participants were excluded from this analysis if they received only 1 dose of an mRNA COVID-19 vaccine, received 2 doses with the second dose <14 days before illness onset, received a non-mRNA COVID-19 vaccine, or received mixed products of an mRNA COVID-19 vaccine (i.e., a different product for each dose).

Vaccine effectiveness against COVID-19-associated hospitalization was estimated using logistic regression, comparing the odds of being fully vaccinated versus unvaccinated between case-patients and controls (including both control groups) using the equation VE = 100 × (1 -odds ratio) (1) . VE over the full surveillance period was assessed, as well as among those with illness onset during March-May and June-July 2021, because of increased circulation of Delta variants in the United States during the latter period (8) . Models were adjusted for potential confounders, including admission date (biweekly intervals), U.S. Department of Health and Human Services region, age, sex, and race/ethnicity. Time-varying VE models were then constructed. First, a binary model was constructed by adding a categorical term (2-12 weeks versus 13-24 weeks) for interval from receipt of the second vaccine § The date of illness onset was used for cases and controls with COVID-19-like illness with median value imputed if missing. For controls without COVID-19like illness, the date of admission minus the median number of days between illness onset and admission for patients with COVID-19 was used for a date of illness onset, also referred to as "illness onset" for this report.

dose (among vaccinated participants) and illness onset. Unvaccinated patients were assigned values of zero days since vaccination. In additional analyses, other specifications of time were considered, including using linear and natural cubic spline terms. Bootstrapping with 1,000 replications was used to estimate 95% CIs. Subgroup analyses included adults aged ≥65 years, patients with immunocompromising conditions, ¶ and patients with three or more categories of chronic medical conditions. A sensitivity analysis was also performed including each of the two control groups in models rather than combining them. Significance of association between VE and time since vaccination was assessed using a likelihood-ratio chi-square test with p-values <0.05 considered statistically significant. Analyses were conducted using R statistical software (version 4.0.3; R Foundation). This activity was determined to be public health surveillance by each participating site and CDC and was conducted consistent with applicable federal law and CDC policy.** After excluding 722 ineligible patients (461 who were not fully vaccinated or unvaccinated, 127 who received a non-mRNA COVID-19 vaccine or mixed vaccines, and 134 who did not meet other inclusion criteria), 3,089 patients were included in the final analysis (1,194 case-patients and 1,895 in the combined control groups) (Table) . The median patient age was 59 years (interquartile range = 46-69 years), 48.7% were female, 56.7% were non-Hispanic White, and 21.1% had an immunocompromising condition. Among case-patients, 141 (11.8%) were fully vaccinated as were 988 (52.1%) controls. Among 454 case-patient specimens with SARS-CoV-2 lineage determined, 242 (53.3%) were identified as Alpha and 74 (16.3%) as Delta (Figure 1 ). Delta variants became the dominant virus in mid-June. Overall VE against hospitalization for COVID-19 was 86% (95% CI = 82%-88%) over the full surveillance period, including 90% (95% CI = 87%-92%) among patients without immunocompromising conditions and 63% (95% CI = 44%-76%) among patients with immunocompromising conditions. VE among patients with illness onset during March-May was 87% (95% CI = 83%-90%), and among those with illness onset during June-July was 84% (95% CI = 79%-89%). In models considering time since vaccination, VE was 86% (95% CI = 82%-90%) ¶ Immunocompromising conditions included having one or more of the following: active solid organ cancer ( during the 2-12 weeks after the second vaccine dose and 84% (95% CI = 77%-90%) 13-24 weeks after the second dose; there was no significant difference in VE between these two periods (p = 0.854). Models treating time since vaccination as linear and as a natural cubic spline with a knot at the median and boundary knots at the 10th and 90th percentiles also showed no significant change in VE over a 24-week period (linear p = 0.400, spline p = 0.234) (Supplementary Figure, https://stacks.cdc.gov/view/cdc/108758). No significant change in VE over a 24-week period was observed within subgroups (all p>0.05) (Figure 2 ). In sensitivity analyses, results were similar using individual control groups and combined controls.

In a multistate network that enrolled adults hospitalized during March-July 2021, effectiveness of 2 doses of mRNA vaccine against COVID-19-associated hospitalization was sustained over a follow-up period of 24 weeks (approximately 6 months). These findings of sustained VE were consistent among subgroups at highest risk for severe outcomes from COVID-19, including older adults, adults with three or more chronic medical conditions, and those with immunocompromising conditions. Overall VE in adults with immunocompromising conditions was lower than that in those without immunocompromising conditions but was sustained over time in both populations.

These data provide evidence for sustained high protection from severe COVID-19 requiring hospitalization for up to 24 weeks among fully vaccinated adults, which is consistent with data demonstrating mRNA COVID-19 vaccines have the capacity to induce durable immunity, particularly in limiting the severity of disease (9, 10) . Alpha variants were the predominant viruses sequenced, although Delta variants became dominant starting in mid-June, consistent with national surveillance data (8) . Because of limited sequenced virus, Delta-specific VE was not assessed. VE was similar during June-July when circulation of Delta increased in the United States compared with VE during March-May when Alpha variants predominated, although further surveillance is needed.

The findings in this report are subject to at least six limitations. First, the follow-up period was limited to approximately 24 weeks since receipt of full vaccination because of the recent authorization of mRNA COVID-19 vaccines in the United States. Additional analyses with longer duration of follow-up since vaccination are warranted. Second, effectiveness over time from authorized non-mRNA COVID-19 vaccines, including Janssen's (Johnson & Johnson) vaccine product, was not assessed because of limited use of this vaccine during the surveillance period. Third, time-varying VE was not assessed 

What is already known about this topic?

COVID-19 mRNA vaccines provide strong protection against severe COVID-19; however, the duration of protection is uncertain.

What is added by this report?

Among 1,129 patients who received 2 doses of a mRNA vaccine, no decline in vaccine effectiveness against COVID-19 hospitalization was observed over 24 weeks. Vaccine effectiveness was 86% 2-12 weeks after vaccination and 84% at 13-24 weeks. Vaccine effectiveness was sustained among groups at risk for severe COVID-19.

What are the implications for public health practice?

mRNA vaccine effectiveness against COVID-19-associated hospitalizations was sustained over 24 weeks; ongoing monitoring is needed as new SARS-CoV-2 variants emerge. To reduce hospitalization, all eligible persons should be offered COVID-19 vaccination.

by lineage because of sample size. Fourth, residual confounding might have been present, although the analysis adjusted for potential confounders, including calendar time and patient age. Fifth, this analysis did not consider VE over time among persons aged <18 years or partially vaccinated persons. Finally, the current analysis only included hospitalized adults and did not include persons with asymptomatic SARS-CoV-2 infection or COVID-19 who did not require hospitalization. Protection against severe COVID-19 resulting in hospitalization was sustained through 24 weeks after vaccination with mRNA COVID-19 vaccines. To reduce their risk for hospitalization, all eligible persons should be offered COVID-19 vaccination. Continued monitoring of VE against infection and severe disease is needed as the elapsed time since vaccination increases and new SARS-CoV-2 variants emerge.

Beth Israel Deaconess Medical Center

Corresponding author: Mark W. Tenforde, media@cdc.gov

Response Team

IVY Network; HAIVEN Investigators. Effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 among hospitalized adults aged ≥65 years-United States

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Effectiveness of SARS-CoV-2 mRNA vaccines for preventing Covid-19 hospitalizations in the United States

Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines

Waning vaccine effectiveness against influenza-associated hospitalizations among adults

Effectiveness of influenza vaccination on influenza-associated hospitalisations over time among children in Hong Kong: a test-negative case-control study

US Department of Health and Human Services, CDC; 2021

SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses

Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection

Abbreviation: VE = vaccine effectiveness.All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Samuel M. Brown reports personal fees from Hamilton, institutional fees from Faron Pharmaceuticals and Sedana, grants from Janssen, the National Institutes of Health (NIH), and the Department of Defense (DoD), book royalties from Oxford University and Brigham Young University, outside the submitted work. Jonathan D. Casey reports grants from NIH, outside the submitted work. Steven Y. Chang was a speaker for La Jolla Pharmaceuticals in 2018 and consulted for PureTech Health in 2020. James D. Chappell reports grants from NIH during the conduct of the study. Matthew C. Exline reports support from Abbott Labs for sponsored talks, outside the submitted work. D. Clark Files reports personal consultant fees from Cytovale and is a data and safety monitoring board (DSMB) member from Medpace, outside the submitted work. Adit A. Ginde reports grants from NIH, DoD, AbbVie, and Faron Pharmaceuticals, outside the submitted work. Michelle N. Gong reports grants from NIH and the Agency for Healthcare Research and Quality (AHRQ), DSMB membership fees from Regeneron, and personal fees from Philips Healthcare, outside the submitted work. Carlos G. Grijalva reports consultancy fees from Pfizer, Merck, and Sanofi-Pasteur; grants from Campbell Alliance/Syneos Health, NIH, the Food and Drug Administration, AHQR, and Sanofi, outside the submitted work. David N. Hager reports salary support from Incyte Corporation, the Marcus Foundation, and EMPACT Precision Medicine via Vanderbilt University Medical Center, outside the submitted work. Natasha Halasa reports grants and nonfinancial support from Sanofi, and Quidel outside the submitted work. Daniel J. Henning reports personal consultant fees from Cytovale and Opticyte. Akram Khan reports grants from United Therapeutics, Johnson & Johnson, 4D Medical, Lung LLC, and Reata Pharmaceuticals, outside the submitted work. Adam S. Lauring reports personal fees from Sanofi and Roche, outside the submitted work. Christopher J. Lindsell reports grants from NIH, DoD, and the Marcus Foundation; contract fees from bioMerieux, Endpoint LLC, and Entegrion Inc, outside the submitted work and has a patent for risk stratification in sepsis and septic shock issued. Emily T. Martin reports personal fees from Pfizer and grants from Merck, outside the submitted work. Arnold S. Monto reports consulting fees from Sanofi-Pasteur and Seqirus outside the submitted work. Ithan D. Peltan reports grants from NIH and Janssen Pharmaceuticals and institutional support from Asahi Kasei Pharma and Regeneron, outside the submitted work. Todd W. Rice reports personal fees from Cumberland Pharmaceuticals, Inc. and personal fees from Avisa Pharma, LLC and Sanofi, outside the submitted work. Wesley H. Self reports consulting fees from Aeprio Pharmaceuticals and Merck outside the submitted work. No other potential conflicts of interest were disclosed.